Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera

References

• Krecak I, Lucijanic M, Verstovsek S. advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep. 2022;17(5):155–169.
   PubMed Web of Science ®Google Scholar
• Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003–1005. DOI:10.1002/ajh.23295
   PubMed Web of Science ®Google Scholar
• Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–368. DOI:10.1016/j.exphem.2014.01.006
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225.
   PubMed Web of Science ®Google Scholar
• Geyer HL, Dueck AC, Scherber RM, et al. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;2015:284706.
   PubMed Web of Science ®Google Scholar
• Mesa R, Palmer J, Eckert R, et al. Quality of life in myeloproliferative neoplasms: symptoms and management implications. Hematol Oncol Clin North Am. 2021;35(2):375–390. DOI:10.1016/j.hoc.2020.12.006
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022;63(3):694–702. DOI:10.1080/10428194.2021.1992756
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881. DOI:10.1038/leu.2013.163
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. DOI:10.1182/blood-2014-05-579136
   PubMed Web of Science ®Google Scholar
• Abu-Zeinah G, Silver RT, Abu-Zeinah K, et al. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36(2):569–572. DOI:10.1038/s41375-021-01447-3
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Krecak I, Soric E, et al. Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis. Leuk Res. 2022;119:106905.
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. DOI:10.1038/s41375-018-0077-1
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. DOI:10.1056/NEJMoa1208500
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124. DOI:10.1056/NEJMoa035572
   PubMed Web of Science ®Google Scholar
• Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: EUROPEAN LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301–311. DOI:10.1016/S2352-3026(22)00046-1 .
   PubMed Web of Science ®Google Scholar
• Mancuso S, Santoro M, Accurso V, et al. Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat. 2020;43(10):526–530. DOI:10.1159/000509376
   PubMed Web of Science ®Google Scholar
• Krečak I, Morić Perić M, Zekanović I, et al. No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera. Oncol Res Treat. 2021;44(4):201–203. DOI:10.1159/000514347
   PubMed Web of Science ®Google Scholar
• Grunwald MR, Kuter DJ, Altomare I, et al.Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL Study. Clin Lymphoma Myeloma Leuk. 2020;20(4):219–225. DOI:10.1016/j.clml.2019.09.601
   PubMed Web of Science ®Google Scholar
• Ghirardi A, Carobbio A, Masciulli A, et al. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: eCLAP follow-up data. Blood Cancer J. 2018;8(1):5. DOI:10.1038/s41408-017-0038-3
   PubMedGoogle Scholar
• Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33(8):1996–2005. DOI:10.1038/s41375-019-0487-8
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–1369. DOI:10.1182/blood-2011-10-387787
   PubMed Web of Science ®Google Scholar
• Tremblay D, Srisuwananukorn A, Ronner L, et al. European LeukemiaNet response predicts disease progression but not thrombosis in polycythemia vera. Hemasphere. 2022;6:e721.
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda JC, Alvarez-Larrán A, Gómez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011;152(1):81–88. DOI:10.1111/j.1365-2141.2010.08430.x
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda JC, Pereira A, Cervantes F, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013;92(6):771–775. DOI:10.1007/s00277-013-1683-7
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786–793. DOI:10.1111/bjh.13886
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–963. DOI:10.1111/j.1365-2141.2009.08019.x
   PubMed Web of Science ®Google Scholar
• Raman I, Pasricha SR, Prince HM, et al. Management of hydroxyurea resistant or intolerant polycythemia vera. Leuk Lymphoma. 2021;62(10):2310–2319. DOI:10.1080/10428194.2021.1901092
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509. DOI:10.1182/blood.2019000428
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386.
   PubMed Web of Science ®Google Scholar
• How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel). 2020;12(7):1954.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122(6):893–901. DOI:10.1182/blood-2012-07-442012
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–3072. DOI:10.1182/blood-2008-03-143537
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418–5424. DOI:10.1200/JCO.2009.23.6075
   PubMed Web of Science ®Google Scholar
• Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165–175. DOI:10.1016/S2352-3026(17)30030-3
   PubMed Web of Science ®Google Scholar
• Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6(1):30. DOI:10.1186/s40164-017-0090-5
   PubMedGoogle Scholar
• Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35(9):2592–2601. DOI:10.1038/s41375-021-01183-8
   PubMed Web of Science ®Google Scholar
• De Oliveira RD, Soret-Dulphy J, Zhao LP, et al. Interferon-Alpha (IFN) therapy discontinuation is feasible in Myeloproliferative Neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Supplement 1):35–36. DOI:10.1182/blood-2020-141223
   Google Scholar
• Yoon SY, Won JH. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms. Blood Res. 2021 Apr 30;56(S1):S44–50.
   PubMedGoogle Scholar
• Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41(1):5–19.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931–2941. DOI:10.1182/blood.2021012743. .
   PubMed Web of Science ®Google Scholar
• Vannucchi Am, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. DOI:10.1056/NEJMoa1409002. .
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226–237. DOI:10.1016/S2352-3026(19)30207-8
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–520. DOI:10.1002/cncr.28441
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821–829. DOI:10.3324/haematol.2016.143644
   PubMed Web of Science ®Google Scholar
• Harrison C, Nangalia J, Boucher RH, et al. Ruxolitinib versus best available therapy for pv intolerant or resistant to hydroxycarbamide in a randomized trial. Blood. 2022;140(Suppl. 1):1781–1783. DOI:10.1182/blood-2022-157273
   Google Scholar
• Alvarez-Larrán A, Garrote M, Ferrer-Marín F, et al. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer. 2022;128(13):2441–2448. DOI:10.1002/cncr.34195
   PubMed Web of Science ®Google Scholar
• Verstovsek S, De Stefano V, Heidel FH, et al. US OPTUM database study in polycythemia vera patients: thromboembolic Events (TEs) with Hydroxyurea (HU) vs Ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure. Blood. 2019;134(Supplement_1):1659. DOI:10.1182/blood-2019-126410 .
   Google Scholar
• Masciulli A, Ferrari A, Carobbio A, et al. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020;4(2):380–386. DOI:10.1182/bloodadvances.2019001158
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Komatsu N, Gill H, et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022;18(27):2999–3009. DOI:10.2217/fon-2022-0596
   PubMed Web of Science ®Google Scholar
• Illés Á, Pinczés LI, Egyed M. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Expert Opin Drug Metab Toxicol. 2021;17(1):3–7.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Besremi. European Medicines Agency website. [cited 2 Dec 2022]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/besremi.
   Google Scholar
• Huang YW, Qin A, Fang J, et al. Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharmacol. 2022;88(5):2396–2407. DOI:10.1111/bcp.15176
   PubMed Web of Science ®Google Scholar
• Besremi [package insert]. [cited 2 Dec 2022]. Available from; https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761166s000lbl.pdf
   Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon Alfa-2b: efficacy and Safety in Different Age Groups. Hemasphere. 2020;4(6):e485. DOI:10.1097/HS9.0000000000000485
   PubMed Web of Science ®Google Scholar
• Zhu M, Wang MX, Li ZR, et al. Population Pharmacokinetics of Ropeginterferon Alfa-2b: a Comparison Between Healthy Caucasian and Chinese Subjects. Front Pharmacol. 2021;12:673492.
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai CY, Tsai CW, et al. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Adv Ther. 2021;38(9):4756–4770. DOI:10.1007/s12325-021-01863-y
   PubMed Web of Science ®Google Scholar
• Miyachi N, Zagrijtschuk O, Kang L, et al. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Clin Drug Investig. 2021;41(4):391–404. DOI:10.1007/s40261-021-01026-5
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–1769. DOI:10.1182/blood-2015-04-637280 .
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Buxhofer-Ausch V, Thaler J, et al. Long-term efficacy and safety of ropeginterferon Alfa-2b in patients with polycythemia vera — final phase I/II peginvera study results. Blood. 2018;132(Supplement 1):3030. DOI:10.1182/blood-2018-99-118584 .
   Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al.; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208. DOI:10.1016/S2352-3026(19)30236-4.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408–1411. DOI:10.1038/s41375-022-01528-x.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175–184. DOI:10.1016/S2352-3026(20)30373-2 .
   PubMed Web of Science ®Google Scholar
• Verger E, Soret-Dulphy J, Maslah N, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8(10):94. DOI:10.1038/s41408-018-0133-0
   PubMedGoogle Scholar
• Gisslinger H, Klade C, Georgiev P, et al. s196: ropeginterferon ALFA-2B achieves patient-specific treatment goals in polycythemia vera: final results from the proud-PV/continuation-PV studies. Hemasphere. 2022;6:97–98.
   Google Scholar
• Kiladjian JJ, Klade C, Georgiev P, et al. Efficacy and safety of long-term ropeginterferon Alfa-2b treatment in patients with low-risk and high-risk Polycythemia Vera (PV). Blood. 2022;140(Supplement 1):9663–9664. DOI:10.1182/blood-2022-156889
   Google Scholar
• Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon Alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of low-PV randomized phase II Trial. Blood. 2022;140(Supplement 1):1797–1799. DOI:10.1182/blood-2022-157255 .
   Google Scholar
• Edahiro Y, Ohishi K, Gotoh A, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116(2):215–227. DOI:10.1007/s12185-022-03341-9 .
   PubMed Web of Science ®Google Scholar
• Huang CE, Wu YY, Hsu CC, et al. Real-world experience with ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc. 2021;120(2):863–873. DOI:10.1016/j.jfma.2020.08.021
   PubMed Web of Science ®Google Scholar
• Okikiolu J, Woodley C, Cadman-Davies L, et al. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep. 2023;19:100360.
   PubMedGoogle Scholar
• Gisslinger H, Grohmann-Izay B, Georgiev P, et al. Final results from PEN-PV study, a single-arm phase 3 trial assessing the ease of self-administrating ropeginterferon alfa-2B using a pre-filled pen in polycythemia vera patients. EHA Lib. 2017;182767:B2053.
   Google Scholar
• Gerds AT, Gotlib J, Ali H, et al. Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(9):1033–1062. DOI:10.6004/jnccn.2022.0046
   PubMedGoogle Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. DOI:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Bjørn ME, Hasselbalch HC. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Rev Hematol. 2017;10(5):393–404.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Silver RT. New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms. Hemasphere. 2021;5(12):e645.
   PubMed Web of Science ®Google Scholar
• Krečak I, Holik H, Morić-Perić M, et al. The impact of statins on the intensity of phlebotomies in polycythemia vera. Ann Hematol. 2020;99(4):911–912. DOI:10.1007/s00277-020-03950-6
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217–1225.
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020;105(9):2262–2272. DOI:10.3324/haematol.2019.235648
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol. 2011;2(1):21–32.
   PubMedGoogle Scholar
• Guglielmelli P, Loscocco GG, Mannarelli C, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11(12):199. DOI:10.1038/s41408-021-00581-6
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Finazzi G, et al. Reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol. 2017;92(11):1131–1136. DOI:10.1002/ajh.24851
   PubMed Web of Science ®Google Scholar
• Dam MJB, Pedersen RK, Knudsen TA, et al. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Eur J Haematol. 2021;107(6):624–633. DOI:10.1111/ejh.13700
   PubMed Web of Science ®Google Scholar
• Dam MJB, Pedersen RK, Knudsen TA, et al. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2. Cancer Med. 2023;12(4):4218–4226. DOI:10.1002/cam4.5285
   PubMed Web of Science ®Google Scholar
• Knudsen TA, Hansen DL, Ocias LF, et al. Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the daliah trial - a randomized controlled phase III clinical trial. Blood. 2018;132(Supplement 1):580. DOI:10.1182/blood-2018-99-111255
   Google Scholar